Toward a more accurate quantitation of the activity of recombinant retroviruses: Alternatives to titer and multiplicity of infection (vol 74, pg 1258, 2000)

被引:43
作者
Andreadis, S
Lavery, T
Davis, HE
Le Doux, JM
Yarmush, ML
Morgan, JR
机构
[1] Shriners Hosp Crippled Children, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Ctr Engn Med, Surg Serv, Boston, MA 02114 USA
关键词
D O I
10.1128/JVI.74.7.3431-3431.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this paper, we present a mathematical model with experimental support of how several key parameters govern the adsorption of active retrovirus particles onto the surface of adherent cells. These parameters, including time of adsorption, volume of virus, and the number, size, and type of target cells, as well as the intrinsic properties of the virus, diffusion coefficient, and half-life (t(1/2)), have been incorporated into a mathematical expression that describes the rate at which active virus particles adsorb to the cell surface. From this expression, we have obtained estimates of C-vo, the starting concentration of active retrovirus particles, In contrast to titer, C-vo is independent of the specific conditions of the assay, The relatively slow diffusion (D = 2 x 10(-8) cm(2)/s) and rapid decay (t(1/2) = 6 to 7 h) of retrovirus particles explain why C-vo values are significantly higher than titer values. Values of C-vo also indicate that the number of defective particles in a retrovirus stock is much lower than previously thought, which has implications especially for the use of retroviruses for in vivo gene therapy. With this expression, we have also computed AVC (active viruses/cell), the number of active retrovirus particles that would adsorb per cell during a given adsorption time. In contrast to multiplicity of infection, which is based on titer and is subject to the same inaccuracies, AVC is based on the physicochemical parameters of the transduction assay and so is a more reliable alternative.
引用
收藏
页码:3431 / 3439
页数:9
相关论文
共 28 条
[11]   TRANSFER OF GENES TO HUMANS - EARLY LESSONS AND OBSTACLES TO SUCCESS [J].
CRYSTAL, RG .
SCIENCE, 1995, 270 (5235) :404-410
[12]  
Forestell SP, 1995, GENE THER, V2, P723
[13]   OPTIMIZATION OF RETROVIRAL VECTOR-MEDIATED GENE-TRANSFER INTO ENDOTHELIAL-CELLS INVITRO [J].
KAHN, ML ;
LEE, SW ;
DICHEK, DA .
CIRCULATION RESEARCH, 1992, 71 (06) :1508-1517
[14]   IMPROVED METHODS OF RETROVIRAL VECTOR TRANSDUCTION AND PRODUCTION FOR GENE-THERAPY [J].
KOTANI, H ;
NEWTON, PB ;
ZHANG, SY ;
CHIANG, YWL ;
OTTO, E ;
WEAVER, L ;
BLAESE, RM ;
ANDERSON, WF ;
MCGARRITY, GJ .
HUMAN GENE THERAPY, 1994, 5 (01) :19-28
[15]  
Le Doux JM, 1999, BIOTECHNOL BIOENG, V63, P654, DOI 10.1002/(SICI)1097-0290(19990620)63:6<654::AID-BIT3>3.3.CO
[16]  
2-T
[17]   Proteoglycans secreted by packaging cell lines inhibit retrovirus infection [J].
LeDoux, JM ;
Morgan, JR ;
Snow, RG ;
Yarmush, ML .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6468-6473
[18]   GENE-TRANSFER BY RETROVIRUS VECTORS OCCURS ONLY IN CELLS THAT ARE ACTIVELY REPLICATING AT THE TIME OF INFECTION [J].
MILLER, DG ;
ADAM, MA ;
MILLER, AD .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (08) :4239-4242
[19]   RETROVIRUS INFECTION - EFFECT OF TIME AND TARGET-CELL NUMBER [J].
MORGAN, JR ;
LEDOUX, JM ;
SNOW, RG ;
TOMPKINS, RG ;
YARMUSH, ML .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6994-7000
[20]   In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [J].
Naldini, L ;
Blomer, U ;
Gallay, P ;
Ory, D ;
Mulligan, R ;
Gage, FH ;
Verma, IM ;
Trono, D .
SCIENCE, 1996, 272 (5259) :263-267